(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2011 (19.05.2011)

PCT

(10) International Publication Number
WO 2011/059839 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/4375* (2006.01)
C07D 487/04 (2006.01) *A61K 31/553* (2006.01)
C07D 519/00 (2006.01) *A61K 31/551* (2006.01)
A61K 31/4985 (2006.01) *A61K 31/55* (2006.01)
A61K 31/5365 (2006.01) *A61P 5/50* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/US2010/054880

(22) International Filing Date:
29 October 2010 (29.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/256,269 29 October 2009 (29.10.2009) US

(71) Applicant *(for all designated States except US)*: **SIRTRIS PHARMACEUTICALS, INC.** [US/US]; 200 Technology Square, Suite 300, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NG, Pui, Yee** [US/US]; c/o Sirtris Pharmaceuticals, Inc., 200 Technology Square, Suite 300, Cambridge, MA 02139 (US). **BLUM, Charles** [US/US]; c/o Sirtris Pharmaceuticals, Inc., 200 Technology Square, Suite 300, Cambridge, MA 02139 (US). **MCPHERSON, Lauren** [US/US]; c/o Sirtris Pharmaceuticals, Inc., 200 Technology Square, Suite 300, Cambridge, MA 02139 (US). **PERNI, Robert, B.** [US/US]; c/o Sirtris Pharmaceuticals, Inc., 200 Technology Square, Suite 300, Cambridge, MA 02139 (US). **VU, Chi, B.** [US/US]; c/o Sirtris Pharmaceuticals, Inc., 200 Technology Square, Suite 300, Cambridge, MA 02139 (US). **AHMED, Mohammed, Mahmood** [GB/US]; c/o GlaxoSmithKline R&D China, Singapore Research Centre, Biopolis At One-North, 11 Biopolis Way; The Helios #06-10/11, Singapore 138667 (SG). **DISCH, Jeremy, S.** [US/US]; c/o Sirtris Pharmaceuticals, Inc., 200 Technology Square, Suite 300, Cambridge, MA 02139 (US).

(74) Agents: **HALSTEAD, David, P.** et al.; Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02199 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/059839 A1

(54) Title: BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS

(57) Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.